Physician profile

Anh Le

Obstetrics & Gynecology · French Camp, CA

NPI 1013095686

$637.13

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$528.50

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Hologic Sales and Service, LLC $167.29 2023 Acessa Provu System, Aptima
Intuitive Surgical, INC. $166.51 2024
Coopersurgical, INC. $105.08 2024 Advincula Delineator Uterine Manipulator
Abbvie INC. $73.05 2022
Merck Sharp & Dohme LLC $42.66 2019-2024 Gardasil, Gardasil 9
Bayer Healthcare Pharmaceuticals INC. $35.10 2019-2023
Aspira Women'S Health INC $26.99 2024 Ova1
Astellas Pharma US INC $20.45 2023 Veozah

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anh Le

$637.13

in general payments reported 2019-2025

Years
2019-2024
Top company
Hologic Sales and Service, LLC

https://glasscript.com/doctor/45768/anh-le

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.